Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Stem Cell Therapy Has Perhaps the Most Potential of All of the New Technologies in Development by Biopharma

Summary

In previous articles, I have written about technologies that have been or promise to be paradigm shifts in drug…
Read more…

The BIO CEO Conference: Highlights from the Meeting and New Investment Perspectives (Subscribers Only)

Back From BIO CEO Conference

I have returned from spending two days at the BIO CEO conference at the Waldorf Astoria…
Read more…

SmithOnStocks Mailbox January 28, 2014

In my writing, I have found that there are some very smart people out there who have interesting questions and…
Read more…

Athersys: The Coming Year Will Define Its Adult Stem Cell Product MultiStem (ATHX, $1.63)

Investment Perspective
This is my initial report on Athersys (ATHX) and its adult stem cell therapy product MultiStem. There are important…
Read more…